Cara Therapeutics, Inc. (NASDAQ:CARA) registered a 7.64% increase, still its new closing price is 287.09% up from the company’s 1 year high of 15.68.It posted 27.53% gains in previous 5 sessions and is now the subject of 0 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 3 buy or better ratings. The 8 stock analysts following this company have an average price target at $22.13, with individual PT in the $17.00-$30.00 range. The shares moved at $16.49, implying that brokerage firms see shares gaining about 91.74% in twelve months time.
Cara Therapeutics, Inc. (CARA) SEC Form 4 News
The stock is getting much attention these days as insiders are offloading shares while they posted a 77.50% rise year to date. A VP-Research & Development at Cara Therapeutics, Inc. (CARA) offloaded shares in a transaction closed on Wednesday April 20, 2016. Menzaghi Frederique Ph.D. sold 6,000 shares in the company at $9 each and collected $54,000 in proceeds. Menzaghi Frederique Ph.D. now owns 123,000 shares in the company after this transaction. A Director in the company, VOGELBAUM MARTIN, disclosed a transaction on Thursday March 17, 2016 that ended up paying $1,948,000 from the purchase of 400,000 shares at $4.87 per share.
Cara Therapeutics, Inc. (NASDAQ:CARA) Upcoming Results on Tap
Cara Therapeutics, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.34 in that period. Sales during the quarter are predicted to arrive at $0.
Cara Therapeutics, Inc. (CARA) Brokerage Update
Over the last six months and over the last three months, the shares of Cara Therapeutics, Inc. (CARA), have changed 185.29% and 135.91%, respectively.